Last 12 months
Inside the activity.
2 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantClass A Common Stock | 685,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004310 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,362,062 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC |
Bilbo PatrickChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 338,674 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004311 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,674 Underlying: Class A Common Stock · 338,674 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC |
Bilbo PatrickChief Operating Officer
|
GrantClass A Common Stock | 187,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004311 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,329 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:22 UTC |
Quintero GilbertoDirector
|
GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004309 · form4.xml · nonDerivative · entry 1 Quintero Gilberto · CIK 0001927023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,670 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:21 UTC |
Korfin Michele IleneDirector
|
GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004308 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,670 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:20 UTC |
Duraibabu PrathyushaDirector
|
GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004304 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,644 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 20:19 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 719 | $3.48 | $2,502.12 |
DisclosureSEC source: 0001062993-24-003767 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,288 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 20:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 646 | $3.48 | $2,248.08 |
DisclosureSEC source: 0001062993-24-003763 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,185 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 799 | $3.48 | $2,780.52 |
DisclosureSEC source: 0001062993-24-003765 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,317 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:18 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 3,788 | $3.48 | $13,182.24 |
DisclosureSEC source: 0001062993-24-003764 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,676,931 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:18 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 804 | $3.48 | $2,797.92 |
DisclosureSEC source: 0001062993-24-003761 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,646 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:17 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 791 | $3.48 | $2,752.68 |
DisclosureSEC source: 0001062993-24-003760 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,011 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:19 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 1,252 | $3.68 | $4,607.36 |
DisclosureSEC source: 0001062993-24-003767 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,007 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:19 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 8,657 | $3.68 | $31,857.76 |
DisclosureSEC source: 0001062993-24-003767 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,259 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 3,643 | $3.68 | $13,406.24 |
DisclosureSEC source: 0001062993-24-003763 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,831 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:18 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 21,516 | $3.68 | $79,178.88 |
DisclosureSEC source: 0001062993-24-003763 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,474 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 3,346 | $3.68 | $12,313.28 |
DisclosureSEC source: 0001062993-24-003765 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,116 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:19 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 18,738 | $3.68 | $68,955.84 |
DisclosureSEC source: 0001062993-24-003765 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,462 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 21,439 | $3.68 | $78,895.52 |
DisclosureSEC source: 0001062993-24-003764 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,680,719 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 65,774 | $3.68 | $242,048.32 |
DisclosureSEC source: 0001062993-24-003764 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,702,158 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 3,513 | $3.68 | $12,927.84 |
DisclosureSEC source: 0001062993-24-003761 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,450 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 18,966 | $3.68 | $69,794.88 |
DisclosureSEC source: 0001062993-24-003761 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,963 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:17 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 4,608 | $3.68 | $16,957.44 |
DisclosureSEC source: 0001062993-24-003760 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,802 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:17 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 24,925 | $3.68 | $91,724.00 |
DisclosureSEC source: 0001062993-24-003760 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,410 Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 16:44 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 17,972 | $4.28 | $76,875.23 |
DisclosureSEC source: 0001062993-24-000799 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,007,134 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.20 to $4.34, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only RED Holdings, LLC has a pecuniary interest in the shares being sold pursuant to the second line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to the second line of Table I of this Form 4, except for Albert Erani, who is the sole manager of RED Holdings, LLC, and who disclaims ownership of the shares held by RED Holdings, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 16:44 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 17,972 | $4.28 | $76,875.23 |
DisclosureSEC source: 0001062993-24-000798 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,007,134 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.20 to $4.34, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only RED Holdings, LLC has a pecuniary interest in the shares being sold pursuant to the second line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to the second line of Table I of this Form 4, except for Albert Erani, who is the sole manager of RED Holdings, LLC, and who disclaims ownership of the shares held by RED Holdings, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 16:44 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 197,921 | $4.37 | $863,984.54 |
DisclosureSEC source: 0001062993-24-000799 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,025,106 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.45, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to the first line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to the first line of Table I of this Form 4. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 16:44 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 197,921 | $4.37 | $863,984.54 |
DisclosureSEC source: 0001062993-24-000798 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,025,106 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.45, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to the first line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to the first line of Table I of this Form 4. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 18:28 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 25,000 | $2.07 | $51,772.50 |
DisclosureSEC source: 0001062993-23-009196 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,223,027 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.0701 to $2.0801, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 18:27 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 25,000 | $2.07 | $51,772.50 |
DisclosureSEC source: 0001062993-23-009195 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,223,027 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.0701 to $2.0801, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:21 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 2,097 | $2.13 | $4,466.61 |
DisclosureSEC source: 0001062993-23-008510 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,916 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:19 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 2,339 | $2.13 | $4,982.07 |
DisclosureSEC source: 0001062993-23-008506 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,990 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:21 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 2,408 | $2.13 | $5,129.04 |
DisclosureSEC source: 0001062993-23-008508 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,200 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:20 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 6,470 | $2.13 | $13,781.10 |
DisclosureSEC source: 0001062993-23-008507 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767,932 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:19 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 2,678 | $2.13 | $5,704.14 |
DisclosureSEC source: 0001062993-23-008505 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,335 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:46 UTC |
Driscoll Michael JosephDirector
|
GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004883 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,284 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:51 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantStock Option (Right to Buy) · Derivative | 118,035 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004892 · form4.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,035 Underlying: Class A Common Stock · 118,035 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:51 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantClass A Common Stock | 99,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004892 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,013 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:45 UTC |
Leibowitz Arthur SDirector
|
GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004881 · form4.xml · nonDerivative · entry 1 Leibowitz Arthur S · CIK 0001467329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,591 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:50 UTC |
Freedman LoriVP and General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 331,076 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004891 · form4.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,076 Underlying: Class A Common Stock · 331,076 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:50 UTC |
Freedman LoriVP and General Counsel
|
GrantClass A Common Stock | 278,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004891 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,329 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:46 UTC |
Giacomin Jon LDirector
|
GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004882 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,603 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC |
Grow BrianChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 345,470 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004890 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,470 Underlying: Class A Common Stock · 345,470 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC |
Grow BrianChief Commercial Officer
|
GrantClass A Common Stock | 291,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004890 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,608 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC |
Bilbo PatrickChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 388,654 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004889 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,654 Underlying: Class A Common Stock · 388,654 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:50 UTC |
Bilbo PatrickChief Operating Officer
|
GrantClass A Common Stock | 327,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004889 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,013 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC |
Francisco DavidChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 287,892 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004888 · form4.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,892 Underlying: Class A Common Stock · 287,892 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC |
Francisco DavidChief Financial Officer
|
GrantClass A Common Stock | 242,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004888 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,929 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 1,655,381 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004887 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655,381 Underlying: Class A Common Stock · 1,655,381 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantClass A Common Stock | 896,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004887 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774,402 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.